BIOVERIS LICENSES VACCINE PORTFOLIO FROM BAXTER HEALTHCARE

BioVeris Corporation (Nasdaq: BIOV) announced today that on August 9, 2005, it completed a Technology License Agreement with Baxter Healthcare Corporation for exclusive patent rights to a broad portfolio of vaccine candidates. Vaccines covered by the Agreement include those for the prevention of diseases caused by Group A streptococci, Group B streptococci, Pneumococci, Group B meningococci, anthrax bacilli and urinary tract infection (UTI) associated E. coli.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-11-2005/0004087190&EDATE=)